Several presentations on key HUTCHMED pipeline assets were featured at ASCO 2023. Notably for lead asset fruquintinib these included sub-group analyses from the global Phase III multi-regional FRESCO-2 study in metastatic colorectal cancer (mCRC), a key element of the recently accepted US and EU filings; real-world China data in 3,000+ patients, where it has been available as Elunate since 2018; and exploratory investigator-sponsored combination studies with PD-1 inhibitors and chemotherapy. Sub...
Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD stren...
HUTCHMED’s transition into a sustainably profitable global biopharma continues to gather momentum, as evidenced in FY22 results, with growing commercial traction in China and pipeline progress with key assets. Global ambitions are now being addressed with partners. Positive fruquintinib FRESCO-2 data, completion of US FDA rolling filing, and execution of a global ex-China commercial and development deal with Takeda brings first launch of a HUTCHMED product outside of China even closer. The $400m...
At the beginning of every year we publish our PSA Perspective, a report intended as a long shelf-life look at the year ahead. This year Pelham Smithers discusses Japan's economy, the outlook for the stock market, and some stand-out themes and developments for the year. These include the digital yen and the demise of live action entertainment in Japan. We also update our noted PSA Focus List of stocks. Table of Contents Overview 3 Background: 4 Japan’s Economic Outlook 5 Ja...
Wie erwartet, wurde die Finanzplanung vor dem Hintergrund der strategischen Zusammenarbeit mit dem Pharma-Multi Huadong Medicine (Huadong) und der abgeschlossenen Barkapitalerhöhung aktualisiert. Der Cash-Reach weitet sich deutlich auf „Mitte 2025“. Angestrebte zusätzliche Partnerschaften (jüngst mit Chiome Bioscience), wie auch angestrebte Erfolgsprämien aus dem Heritage-Portfolio sind darin nicht enthalten. Die Entwicklungsfortschritte in den ATAC®-Programmen bzw. in der wachsenden Zahl der P...
The general evaluation of TAKEDA PHARMACEUTICAL (JP), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Positive. As of the analysis date April 1, 2022, the closing price was JPY 3,544.0...
Although the Japanese economy, politics and stock market seem to be where they were this time last year, there is a seismic shift going on in the way the Japanese stock market behaves that could make investing in Japan in 2022 quite different to previous years. We look at how and why this shift has taken place and what it means for investing in Japan in the coming year.
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
OSAKA, Japon--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited () (« Takeda ») a annoncé aujourd'hui la signature de la vente annoncée précédemment d'un portefeuille contenant certains actifs pharmaceutiques OTC et médicaments prescrits sur ordonnance dans plusieurs pays du Proche-Orient, du Moyen-Orient et d'Afrique au sein de son unité commerciale Croissance et Marchés Émergents (BU GEM ) à Acino pour une valeur totale supérieure à 200 millions de dollars. La transaction inclut une sélection d'environ 30 produits pharmaceutiques OTC vendus sur ordonnance. Ces produits continueront ...
OSAKA, Japon--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited () (« Takeda ») a annoncé aujourd'hui avoir signé un accord visant la cession, à Hypera S.A. (« Hypera Pharma »), la plus importante société pharmaceutique du Brésil, qui se trouve en tête du marché des prescriptions de produits de marque, de santé grand public et de génériques, d'un portefeuille de certains produits non essentiels exclusivement en Amérique latine, pour une valeur totale de 825 millions de dollars. Ce portefeuille inclut des produits pharmaceutiques en vente libre et sur ordonnance vendus au Brésil, au Mex...
OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited () (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select over-the-counter (OTC) and prescription pharmaceutical assets in a number of Near East, Middle East and Africa countries within its Growth and Emerging Markets Business Unit (GEM BU) to Acino for a total value in excess of $200 million USD. The transaction includes approximately 30 select prescription pharmaceutical and OTC products. These products will continue to be made available by Takeda in other parts of the world....
OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited () (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core products exclusively in Latin America to Hypera S.A. (“Hypera Pharma”), Brazil’s largest pharmaceutical company with a leading position in branded prescriptions, consumer health and branded generics, for a total value of $825M USD. The portfolio includes over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru, which are part of Takeda’s Growth &...
We updated our model and estimates to reflect narrow-moat Takeda’s new reporting segments, balance sheet, and guidance. Our fair value remains unchanged at JPY 5,100 per share. Despite management’s affirmation of the company’s long-term margin expansion, the stock trades at a 23% discount to our fair value. Our revenue assumptions have fallen to JPY 3.3 trillion in 2028, whereas we projected JPY 4.0 trillion in our previous model. This incorporates several changes, including lower foreca...
We updated our model and estimates to reflect narrow-moat Takeda’s new reporting segments, balance sheet, and guidance. Our fair value remains unchanged at JPY 5,100 per share. Despite management’s affirmation of the company’s long-term margin expansion, the stock trades at a 23% discount to our fair value. Our revenue assumptions have fallen to JPY 3.3 trillion in 2028, whereas we projected JPY 4.0 trillion in our previous model. This incorporates several changes, including lower foreca...
We updated our model and estimates to reflect narrow-moat Takeda’s new reporting segments, balance sheet, and guidance. Our fair value remains unchanged at JPY 5,100 per share. Despite management’s affirmation of the company’s long-term margin expansion, the stock trades at a 23% discount to our fair value. Our revenue assumptions have fallen to JPY 3.3 trillion in 2028, whereas we projected JPY 4.0 trillion in our previous model. This incorporates several changes, including lower foreca...
Takeda reported full-year earnings with lower-than-expected IFRS numbers, but better-than-expected core earnings after removing the one-off cash charges from acquisition-related costs, and non-cash costs from purchase accounting. Additionally, management gave updated guidance on synergies and cost-cutting initiatives that is in line with our positive view of the company’s long-term margin expansion ability. We are reviewing our model but we do not expect a major change in fair value. Takeda r...
Takeda reported full-year earnings with lower-than-expected IFRS numbers, but better-than-expected core earnings after removing the one-off cash charges from acquisition-related costs, and non-cash costs from purchase accounting. Additionally, management gave updated guidance on synergies and cost-cutting initiatives that is in line with our positive view of the company’s long-term margin expansion ability. We are reviewing our model but we do not expect a major change in fair value. Takeda re...
CAMBRIDGE, Massachusetts, et OSAKA, Japon--(BUSINESS WIRE)-- Takeda annonce lors du congrès annuel 2019 de l’EAHAD les résultats de l’essai PROPEL de phase IIIb/IV – une étude de prophylaxie guidée par la pharmacocinétique randomisée, première du genre, évaluant des niveaux supérieurs de facteur VIII dans l’hémophilie A Takeda Pharmaceutical Company Limited () (« Takeda »), le leader biotechnologique mondial dans le domaine des maladies rares, a annoncé aujourd’hui les résultats de son essai clinique de phase IIIb/I...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.